SEC Form 4 · accession 0001209191-15-005450
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Fust
Director
Period of report
Jan 16, 2015
Accepted (ET)
Jan 21, 2015 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $25.15 | Jan 16, 2015 | A | 12,500 | A | — | Jan 16, 2022 | Common Stock | 12,500 | 12,500 | D |
Explanation of responses
- F1The option will vest 100% on January 1, 2016.